National Survey Identifies Significant Growth in Receptor Agonist Utilization for Weight Management

Recent national survey data shows that 11 percent of adults currently use a glucagon-like peptide-1 receptor agonist medication for weight loss. This marks a sharp increase from 8 percent in 2025 and 3 percent in 2024. Public awareness of these prescription drugs has also grown significantly during this time. Notably, 91 percent of individuals now say they are familiar with these therapies, compared to 80 percent two years ago.

Authorized clinicians prescribe these options under several different brand names. These medications include liraglutide, semaglutide and tirzepatide. Federal regulators approved these compounds for weight management between 2021 and 2023. Given this timeline, 15 percent of adults report having tried one of these prescription therapies at some point.

Self-reported obesity rates peaked at 39.9 percent in 2022 and have since dropped to 36.4 percent. Research analysts link this decline directly to the increased use of receptor agonists. Additionally, historical data shows that obesity affected 28.4 percent of individuals in 2016 and 25.5 percent in 2008. Thus, the recent decrease marks a significant turnaround in long-term health trends.

Among current users, 68 percent report using traditional brand-name products. Meanwhile, 19 percent of patients use compounded or custom-made formulations. The remaining 12 percent of respondents do not know which specific type they are receiving. Many individuals who switch to compounded alternatives cite lack of insurance coverage as the main reason.

Clinical evidence shows that these medications can cause both negative and surprising positive effects. Common side effects include severe nausea and changes in smell or taste. On the other hand, ongoing medical studies suggest these drugs may lower alcohol cravings and reduce violent behavior. Clinicians emphasize that individual responses to treatment can vary greatly among different patient groups.

Patient age also seems to play a significant role in treatment effectiveness. National polling indicates that adults over the age of 65 have reduced efficacy compared to younger groups. This finding has important implications for future healthcare coverage policies. Therefore, physicians must consider these age-related differences when creating personalized treatment plans.

Pharmaceutical companies continue to explore delivery options beyond traditional subcutaneous injections. Specifically, federal regulators approved an oral formulation of semaglutide in late 2025. Other oral formulations are currently being actively developed in various manufacturing labs. These advancements will likely increase patient access and improve long-term adherence to treatment.

The rapid rise in usage raises ongoing questions about safety monitoring and managing healthcare costs. The Food and Drug Administration continues to monitor adverse event reports as use increases. Gaps in insurance coverage remain a significant barrier for many seeking brand-name medications. Thus, regulatory agencies and insurers face new challenges regarding pricing and oversight.